NNRCO will be composed of multiple research departments, as well as a strategic and business operations department, led by Suzie Markin. In 2017, NNRCO has 4 research departments.

NNRCO Organisation Chart

Read image text 

Department of Discovery Bioinformatics  

JNGJ

Led by Dr. Jan Nygaard Jensen, this department aims to go beyond data analysis services to direct and drive Type 2 diabetes target discovery using multiple bioinformatics approaches. The goal is to closely link wet lab experimental findings to provide a feedback loop of result prioritization and hypothesis generation. Our bioinformatic work will be anchored in strong biology, target networks and the druggable genome.

 

The Department of Advanced Genomics

QWS2.jpgLed by Dr. Quin Wills, this department aims to discover and validate modifiers of nutrient flux, with a focus on the relationship between fatty liver disease and insulin resistance. They do this using cellular genomics methods such as single-cell sequencing and crispr, both for screening and building spatiotemporal models of liver function at a cellular resolution.

 

 

THE DEPARTMENT OF STEM CELL ENGINEERING

nolbLed by Dr. Nicola Beer, this department aims to discover novel secreted factors and corresponding signalling pathways which modify beta-cell function, health, and viability. It combines in vitro-differentiated human stem cell-derived models with CRISPR and other genomic targeting techniques to assay beta-cell function from a single gene up to a genome-wide scale. Understanding the genes and pathways underlying beta-cell function (and dysfunction) highlights potential targets for new Type 2 Diabetes therapeutics. 

 

 THE DEPARTMENT OF HIGH-THROUGHPUT IMAGING

JMJH

Led by Prof. James Johnson, this department seeks to identify novel secreted proteins and peptides that modulate pancreatic beta-cell function and survival using robotic live-cell microscopy and other high-throughput cell physiology approaches. The identified proteins and peptides will represent potential targets for disease modifying type 2 diabetes therapy. 

 

 

 

Additional Departments will be added in 2018, including ones dedicated to cell physiology, in vivo physiology, and proteomics. 

Page updated 05/10/2017